---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-029211"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T19:28:33.624267+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Globus Medical to acquire NuVasive in $3.1B all-stock merger; 0.75 exchange ratio

## Summary
- Exchange ratio: 0.75 GMED shares per NUVA share; implied price $57.72; equity value $3.1B.
- Combined ownership: GMED shareholders 72%, NUVA shareholders 28% on fully diluted basis.
- Expects mid-30% EBITDA margin in 3 years and ~$170M in identified cost synergies.
- Dan Scavilla to remain CEO; Chris Barry to support integration; board expands to 11 (3 from NuVasive).
- Transaction expected to close mid-2023, subject to shareholder and regulatory approvals.

## SEC filing metadata
- accession: 0001193125-23-029211
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000119312523029211/0001193125-23-029211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000119312523029211/d434853d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-029211
- JSON: https://secwatch.observer/filing/0001193125-23-029211.json
- Plain text: https://secwatch.observer/filing/0001193125-23-029211.txt

## Key facts
- Earnings Releases
  GLOBUS MEDICAL INC reported preliminary financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: preliminary results
  source text: On February 9, 2023, Globus Medical, Inc. (“Globus Medical” or the “Company”) issued the Joint Press Release (as defined in Item 7.01 below) which contained certain preliminary financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000119312523029211/0001193125-23-029211-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.